BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs2300478
,
LEP
,
cell-cell adhesion
,
Breast Cancer
,
Pancreas
,
Autoimmunity
,
Doxycycline
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
cd274 protein human
Summary
General Info
Curated Studies
Most Correlated Studies
Colorectal cancer (HT29 & HCT116) and melanoma PES43 cells treated with Nivolumab, sPD-L1 or both
CD8+ T cells from OT-1 mice after exposure to PD-L1
Renal cell carcinoma PDL1+ biopsies of nivolumab non-responders and partial and complete responders
Melanoma A375 cells overexpressing CD274, MCL1, JUNB, or B3GNT2
Primary and metastatic melanomas - PD-L1 positive or negative
Explore Curated Studies Results
Literature
Most Relevant Literature
Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy.
The regulation of N6-methyladenosine modification in PD-L1-induced anti-tumor immunity.
Lentinan-laden microspheres reprogram the tumor microenvironment and improve anti-PD-L1 efficacy.
Machine learning predicts cancer subtypes and progression from blood immune signatures.
Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Neurofilament Light Chain ,Chitinase-3 Like-1 Proteins and Plasmacytoid Dendritic Cells in Multiple …
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GU…
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' …
Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer
SMMART Adaptive Clinical Treatment (ACT) Trial
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ